Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
PRNewswire - October 28, 2002
The FHI study is designed to evaluate the safety and efficacy of the antiretroviral tenofovir disoproxil fumarate (tenofovir DF) as a method of reducing the risk of HIV infection in sexually active adults who are regularly exposed to the virus. The study will also assess the acceptability of, and adherence to, a regimen of one tenofovir DF tablet taken once daily. Gilead Sciences developed tenofovir DF and is supplying the drug for this study. As an antiviral treatment, tenofovir DF has several characteristics that make it a promising candidate as a method of HIV prevention, including its safety, efficacy, pharmacokinetic and resistance profiles.
Although condoms are a proven method for preventing the spread of sexually transmitted diseases, including HIV, women often are unable to successfully negotiate the use of this method by their partners. Thus, the urgency for expanded prevention options is greatest for women. If shown to be safe and effective in this setting, tenofovir DF could be an HIV prevention method used by men or women.
"It is imperative that we not only strive to develop new drugs, but that we also consider new uses for existing ones, such as tenofovir DF, which has tremendous potential as a dual HIV treatment and prevention technology," said Ward Cates, president of FHI's Institute for Family Health. "Our goal with this unique study is to help guide public health decision-making that spurs the delivery of HIV prevention tools to men and women around the world."
"Convenient, reliable and effective methods of HIV prevention are urgently needed," said Helene Gayle, director HIV/AIDS and TB at the Bill & Melinda Gates Foundation. "Previous experience with antiretroviral therapy in reducing the acquisition risks in healthcare workers and newborns exposed to HIV gives us hope that they may be an effective method of preventing sexual transmission of HIV."
Dr. Gayle serves as co-chair of the Global HIV Prevention Working Group, which this summer issued its blueprint for action. In its report, the working group highlighted the need for new, novel technologies to reduce transmission of HIV. The working group also underscored the importance of efforts that will empower women to decrease their vulnerability to HIV.
About Tenofovir DF
Tenofovir DF is marketed as Viread(R) for the treatment of HIV infection in the United States and Europe by Gilead. Tenofovir DF, or Viread, is the first nucleotide analogue reverse transcriptase inhibitor (NtRTI) approved for the treatment of HIV. It was approved in the United States in October 2001 and in the European Union in February 2002. The drug works by blocking reverse transcriptase, an enzyme involved in the replication of HIV. The approved dose of tenofovir DF for the treatment of HIV infection is 300 mg once daily taken orally with a meal.
The Bill & Melinda Gates Foundation is dedicated to improving people's lives by sharing advances in health and learning with the global community. Led by Bill Gates' father, William H. Gates, Sr., and Patty Stonesifer, the Seattle-based foundation has an endowment of approximately $24 billion.
Family Health International is a non-profit organization with three decades of global leadership in health research, service delivery and technical assistance in reproductive health and HIV prevention. With corporate headquarters in Research Triangle Park, NC, FHI operates management centers in Washington, DC, Bangkok and Nairobi and implements programs through offices in more than 40 countries.
On the Internet:
Bill & Melinda Gates Foundation, http://www.gatesfoundation.org Family Health International, www. fhi.org Gilead Sciences, http://www.gilead.com
SOURCE The Bill & Melinda Gates Foundation
Web Site: http://www.gatesfoundation.org
021028
PR021037
Copyright © 2002 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .